Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Allogene, Springworks announce first patient dosed in Phase 1 study of ALLO-715 » 08:38
04/12/21
04/12
08:38
04/12/21
08:38
ALLO

Allogene Therapeutics

$32.83 /

-0.83 (-2.47%)

, SWTX

SpringsWorks Therapeutics

$69.00 /

-2.23 (-3.13%)

Allogene Therapeutics…

Allogene Therapeutics (ALLO) and SpringWorks Therapeutics (SWTX) announced that the first patient has been dosed in a Phase 1 trial evaluating ALLO-715, Allogene's investigational anti-B-cell maturation antigen AlloCAR T therapy, in combination with nirogacestat, SpringWorks' investigational gamma secretase inhibitor, in patients with relapsed or refractory multiple myeloma. "We are pleased to have initiated this portion of the UNIVERSAL trial and look forward to investigating ALLO-715 in combination with nirogacestat as part of our comprehensive anti-BCMA strategy aimed at bringing an off-the-shelf cell therapy to patients with relapsed or refractory multiple myeloma," said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene Therapeutics.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$69.00 /

-2.23 (-3.13%)

ALLO Allogene Therapeutics
$32.83 /

-0.83 (-2.47%)

ALLO Allogene Therapeutics
$32.83 /

-0.83 (-2.47%)

03/01/21 H.C. Wainwright
Allogene Therapeutics price target raised to $43 from $40 at H.C. Wainwright
01/26/21 Stifel
Allogene Therapeutics upgraded to Buy from Hold at Stifel
12/28/20 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $87 from $73 at H.C. Wainwright
12/10/20 H.C. Wainwright
Allogene Therapeutics assumed with a Buy at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$69.00 /

-2.23 (-3.13%)

03/30/21 JPMorgan
SpringsWorks Therapeutics added to Analyst Focus List at JPMorgan
02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
SWTX SpringsWorks Therapeutics
$69.00 /

-2.23 (-3.13%)

ALLO Allogene Therapeutics
$32.83 /

-0.83 (-2.47%)

  • 02
    Mar
  • 08
    Oct
  • 02
    Jun
ALLO Allogene Therapeutics
$32.83 /

-0.83 (-2.47%)

SWTX SpringsWorks Therapeutics
$69.00 /

-2.23 (-3.13%)

Thursday
Options
Five new option listings and one option delisting on April 8th » 08:30
04/08/21
04/08
08:30
04/08/21
08:30
AMTI

Applied Molecular Transport

$55.63 /

-0.23 (-0.41%)

, AREC

American Resources

$3.65 /

-0.21 (-5.44%)

, AVO

Mission Produce

$19.85 /

+0.03 (+0.15%)

, COUR

Coursera

$58.03 /

+1.84 (+3.27%)

, SWTX

SpringsWorks Therapeutics

$70.38 /

-0.96 (-1.35%)

, MTSC

MTS Systems

$58.50 /

+ (+0.00%)

New option listings for…

New option listings for April 8th include Applied Molecular Transport Inc (AMTI), American Resources Corporation (AREC), Mission Produce Inc (AVO), Coursera Inc (COUR), and SpringWorks Therapeutics Inc (SWTX). Option delistings effective April 8th include MTS Systems Corporation (MTSC).

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$70.38 /

-0.96 (-1.35%)

MTSC MTS Systems
$58.50 /

+ (+0.00%)

AVO Mission Produce
$19.85 /

+0.03 (+0.15%)

AREC American Resources
$3.65 /

-0.21 (-5.44%)

AMTI Applied Molecular Transport
$55.63 /

-0.23 (-0.41%)

AMTI Applied Molecular Transport
$55.63 /

-0.23 (-0.41%)

03/23/21 Jefferies
Applied Molecular Transport price target raised to $75 from $38 at Jefferies
03/17/21 JMP Securities
Applied Molecular Transport initiated with an Outperform at JMP Securities
06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
AREC American Resources
$3.65 /

-0.21 (-5.44%)

02/23/21 Roth Capital
American Resources initiated with a Buy at Roth Capital
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 H.C. Wainwright
American Resources initiated with a Buy at H.C. Wainwright
10/09/20 Maxim
American Resources Corp. downgraded to Hold from Buy at Maxim
AVO Mission Produce
$19.85 /

+0.03 (+0.15%)

03/23/21 Citi
Mission Produce downgraded to Neutral from Buy at Citi
03/15/21 DA Davidson
Mission Produce price target raised to $27 from $18 at DA Davidson
03/11/21
Fly Intel: Top five analyst downgrades
03/11/21 JPMorgan
Mission Produce downgraded to Neutral on valuation at JPMorgan
COUR Coursera
$58.03 /

+1.84 (+3.27%)

SWTX SpringsWorks Therapeutics
$70.38 /

-0.96 (-1.35%)

03/30/21 JPMorgan
SpringsWorks Therapeutics added to Analyst Focus List at JPMorgan
02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
MTSC MTS Systems
$58.50 /

+ (+0.00%)

12/09/20 Colliers
MTS Systems downgraded to Neutral from Buy at Colliers
08/20/20 Colliers
MTS Systems initiated with a Buy at Colliers
04/17/20 Wells Fargo
MTS Systems downgraded to Underweight from Equal Weight at Wells Fargo
04/17/20 Wells Fargo
MTS Systems downgraded to Underweight from Equal Weight at Wells Fargo
SWTX SpringsWorks Therapeutics
$70.38 /

-0.96 (-1.35%)

MTSC MTS Systems
$58.50 /

+ (+0.00%)

AVO Mission Produce
$19.85 /

+0.03 (+0.15%)

AMTI Applied Molecular Transport
$55.63 /

-0.23 (-0.41%)

  • 01
    Apr
  • 31
    Mar
  • 02
    Mar
  • 08
    Oct
  • 01
    Oct
  • 05
    Jun
COUR Coursera
$58.03 /

+1.84 (+3.27%)

AVO Mission Produce
$19.85 /

+0.03 (+0.15%)

Over a week ago
Hot Stocks
SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study » 06:33
04/01/21
04/01
06:33
04/01/21
06:33
SWTX

SpringsWorks Therapeutics

$73.70 /

+5.31 (+7.76%)

, JNJ

Johnson & Johnson

$164.33 /

-0.68 (-0.41%)

SpringWorks Therapeutics…

SpringWorks Therapeutics (SWTX) announced that the first patient has been dosed in a Phase 1b clinical trial evaluating nirogacestat, an investigational gamma secretase inhibitor being developed by SpringWorks, in combination with teclistamab, an investigational bispecific antibody targeting B-cell maturation antigen and CD3 being developed by Janssen (JNJ) Research & Development, in patients with relapsed or refractory multiple myeloma. The Phase 1b trial, which is part of a multi-arm trial being conducted by Janssen, is an open-label study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with teclistamab in patients with relapsed or refractory multiple myeloma. The trial is being advanced pursuant to a clinical collaboration and supply agreement that SpringWorks entered into with Janssen Biotech, Inc. in September 2020. Under the terms of the agreement, Janssen is assuming all costs associated with the Phase 1b study, other than expenses related to the supply of nirogacestat. SpringWorks has formed a joint oversight committee with Janssen to coordinate the sharing of study results, regulatory and other activities in connection with the study. In addition to its ongoing clinical collaborations with BCMA-directed therapies, SpringWorks is conducting a global Phase 3, double-blind, randomized, placebo-controlled clinical trial to evaluate nirogacestat as a monotherapy in adults with progressing desmoid tumors.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$73.70 /

+5.31 (+7.76%)

JNJ Johnson & Johnson
$164.33 /

-0.68 (-0.41%)

SWTX SpringsWorks Therapeutics
$73.70 /

+5.31 (+7.76%)

03/30/21 JPMorgan
SpringsWorks Therapeutics added to Analyst Focus List at JPMorgan
02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
JNJ Johnson & Johnson
$164.33 /

-0.68 (-0.41%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
SWTX SpringsWorks Therapeutics
$73.70 /

+5.31 (+7.76%)

JNJ Johnson & Johnson
$164.33 /

-0.68 (-0.41%)

  • 02
    Mar
  • 08
    Oct
JNJ Johnson & Johnson
$164.33 /

-0.68 (-0.41%)

JNJ Johnson & Johnson
$164.33 /

-0.68 (-0.41%)

JNJ Johnson & Johnson
$164.33 /

-0.68 (-0.41%)

Recommendations
SpringsWorks Therapeutics added to Analyst Focus List at JPMorgan » 07:23
03/30/21
03/30
07:23
03/30/21
07:23
SWTX

SpringsWorks Therapeutics

$65.62 /

-1.59 (-2.37%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama added SpringsWorks Therapeutics shares to the firm's Analyst Focus List as a Growth idea "ahead of a catalyst-filled 2021." The analyst sees a high probability of success for the Phase 3 DeFi results for nirogacestat in desmoid tumors expected in the second half of 2021. Further, based on physician discussions and data, Rama believes the mirdametinib Phase 2b interim results are being underappreciated. The recent pullback in SpringsWorks shares has created a more compelling entry point ahead of Phase 3 DeFi results for nirogacestat, Rama tells investors in a research note. He keeps an Overweight rating on the shares with a $101 price target.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$65.62 /

-1.59 (-2.37%)

SWTX SpringsWorks Therapeutics
$65.62 /

-1.59 (-2.37%)

02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$65.62 /

-1.59 (-2.37%)

  • 02
    Mar
  • 08
    Oct
Hot Stocks
SpringsWorks Therapeutics names Bhavesh Ashar as Chief Commercial Officer » 06:34
03/22/21
03/22
06:34
03/22/21
06:34
SWTX

SpringsWorks Therapeutics

$68.29 /

-0.52 (-0.76%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

SpringWorks Therapeutics…

SpringWorks Therapeutics (SWTX) announced that Bhavesh Ashar has been appointed Chief Commercial Officer. Ashar has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served as Senior Vice President, General Manager of U.S. Oncology at Bayer Healthcare (BAYRY). Ashar will build and lead commercial operations at SpringWorks as the company continues to advance its diversified targeted oncology portfolio, which includes two potentially registrational rare oncology programs.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$68.29 /

-0.52 (-0.76%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

SWTX SpringsWorks Therapeutics
$68.29 /

-0.52 (-0.76%)

02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
BAYRY Bayer
$0.00 /

+ (+0.00%)

03/19/21 Deutsche Bank
Bayer price target raised to EUR 66 from EUR 63 at Deutsche Bank
03/11/21 Societe Generale
Bayer price target lowered to EUR 59 from EUR 68 at Societe Generale
03/03/21 Berenberg
Bayer price target raised to EUR 68 from EUR 60 at Berenberg
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
SWTX SpringsWorks Therapeutics
$68.29 /

-0.52 (-0.76%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

  • 02
    Mar
  • 08
    Oct
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Conference/Events
SpringsWorks Therapeutics management to meet virtually with Wedbush » 04:55
03/22/21
03/22
04:55
03/22/21
04:55
SWTX

SpringsWorks Therapeutics

$68.29 /

-0.52 (-0.76%)

Virtual Meeting to be…

Virtual Meeting to be held on March 22.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$68.29 /

-0.52 (-0.76%)

SWTX SpringsWorks Therapeutics
$68.29 /

-0.52 (-0.76%)

02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$68.29 /

-0.52 (-0.76%)

  • 02
    Mar
  • 08
    Oct
Conference/Events
SpringsWorks Therapeutics management to meet virtually with Wedbush » 12:35
03/15/21
03/15
12:35
03/15/21
12:35
SWTX

SpringsWorks Therapeutics

$76.74 /

-2.22 (-2.81%)

Virtual Meeting to be…

Virtual Meeting to be held on March 22.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$76.74 /

-2.22 (-2.81%)

SWTX SpringsWorks Therapeutics
$76.74 /

-2.22 (-2.81%)

02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$76.74 /

-2.22 (-2.81%)

  • 02
    Mar
  • 08
    Oct
Over a month ago
Syndicate
SpringsWorks Therapeutics 1.2M share Block Trade priced at $84.00 » 09:27
03/02/21
03/02
09:27
03/02/21
09:27
SWTX

SpringsWorks Therapeutics

$86.95 /

+0.34 (+0.39%)

The deal priced at low…

The deal priced at low end of $84.00-$84.50 range. Morgan Stanley is acting as sole book running manager for the offering.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$86.95 /

+0.34 (+0.39%)

SWTX SpringsWorks Therapeutics
$86.95 /

+0.34 (+0.39%)

02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$86.95 /

+0.34 (+0.39%)

  • 02
    Mar
  • 08
    Oct
Recommendations
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays » 07:18
02/26/21
02/26
07:18
02/26/21
07:18
SWTX

SpringsWorks Therapeutics

$89.12 /

-4.42 (-4.73%)

Barclays analyst Peter…

Barclays analyst Peter Lawson raised the firm's price target on SpringsWorks Therapeutics to $105 from $92 and keeps an Overweight rating on the shares following the Q4 results.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$89.12 /

-4.42 (-4.73%)

SWTX SpringsWorks Therapeutics
$89.12 /

-4.42 (-4.73%)

02/25/21 H.C. Wainwright
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright
01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
12/28/20 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $87 from $73 at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$89.12 /

-4.42 (-4.73%)

  • 08
    Oct
Recommendations
SpringsWorks price target raised to $124 from $101 at H.C. Wainwright » 10:32
02/25/21
02/25
10:32
02/25/21
10:32
SWTX

SpringsWorks Therapeutics

$92.92 /

-0.62 (-0.66%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns raised the firm's price target on SpringsWorks Therapeutics to $124 from $101 and reiterates a Buy rating on the shares. Mirdametinib demonstrated "encouraging" early efficacy, with a potentially differentiated safety profile, Burns tells investors in a research note. The analyst is "incrementally positive" after SpringWorks presented interim results from the registrational Phase 2b ReNeu trial, which is evaluating mirdametinib for the treatment of adult and pediatric patients with inoperable neurofibromatosis type 1 associated plexiform neurofibromas.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$92.92 /

-0.62 (-0.66%)

SWTX SpringsWorks Therapeutics
$92.92 /

-0.62 (-0.66%)

01/22/21 Barclays
SpringsWorks Therapeutics price target raised to $92 from $83 at Barclays
01/19/21 H.C. Wainwright
SpringsWorks price target raised to $101 from $87 at H.C. Wainwright
12/28/20 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $87 from $73 at H.C. Wainwright
12/17/20 JPMorgan
SpringsWorks Therapeutics price target raised to $85 from $57 at JPMorgan
SWTX SpringsWorks Therapeutics
$92.92 /

-0.62 (-0.66%)

  • 08
    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.